查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088481

肺動脈高壓市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、治療方法、病患類型、最終使用者和通路分類）

Pulmonary Arterial Hypertension Market by Drug Class, Route Of Administration, Treatment Type, Patient Type, End User, Distribution - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺動脈高壓市場規模將達到 164.5 億美元，複合年成長率為 7.73%。

主要市場統計數據
基準年 2025 97.7億美元
預計年份：2026年 104.6億美元
預測年份 2032 164.5億美元
複合年成長率 (%) 7.73%

肺動脈高壓（PAH）是一種罕見且進行性的肺動脈高壓，其特徵是肺動脈微矽酸鹽重塑、肺血管阻力增加，最終導致右心臟衰竭。世界衛生組織（WHO）將其歸類為1類肺動脈高壓，包括特發性、遺傳性、藥物/毒素相關性和結締組織疾病相關性PAH。流行病學研究和主要登記數據一致表明，雖然PAH的盛行率低於慢性心肺疾病，但它會造成嚴重的臨床負擔，導致頻繁住院，並產生巨大的治療費用。

目前，肺動脈高壓 (PAH) 的治療主要基於三條已確立的路徑：內皮素受體拮抗劑、一氧化氮-cGMP 訊號通路和前列腺環素訊號通路。隨著疾病修正治療、基於風險的早期治療強化以及更積極地利用真實世界數據 (REW)，該市場正蓄勢待發，即將進入一個新階段。對於製藥公司而言，成長與市場市場進入策略的密切相關，這些策略需展現出對差異化臨床結果、聯合治療定位、生命週期管理以及風險評分（重點關注功能分級、6 分鐘步行距離、NT-proBNP、住院率和生存率）的可衡量影響。

肺動脈高壓治療前景的變革性變化

肺動脈高壓 (PAH) 治療領域最顯著的轉變是從症狀控制轉向風險為基礎的早期療育。 2022 年 ESC/ERS 肺動脈高壓指南重申了全面的診斷檢測、轉診至專科機構以及多參數風險評估的重要性，同時建議對許多患者進行早期或早期聯合治療。這進一步提升了那些能夠納入階梯式或聯合治療且不影響安全性、耐受性或用藥依從性的療法的商業性價值。

人工智慧對製藥業的累積影響（PAH）

人工智慧正在對肺動脈高壓（PAH）的藥物研發、診斷、臨床試驗設計和商業化等各個階段產生累積影響。在藥物研發方面，機器學習正被用於分析體學資料集、識別分子亞型、重新利用現有化合物以及篩選針對疾病進展高風險患者的臨床試驗。由於PAH患者數量少、患者群體異質性高且診斷往往延遲，這些方法在PAH領域尤其重要。

全球多環芳烴市場的關鍵區域洞察

北美仍然是肺動脈高壓領域商業性程度最高的地區，其中美國發揮主導作用。在美國，專科藥局、肺動脈高壓中心、先進療法的普及以及保險公司的准入管理共同決定了治療的可近性。在加拿大，專科網路、公共醫療保險報銷系統和既定的臨床實踐標準都發揮了重要作用，儘管各省的治療准入時間可能有所不同。歐洲的肺動脈高壓治療體係也同樣成熟，德國、法國、義大利、西班牙和英國受益於醫療技術評估、指南遵循、國家醫療保險報銷決策以及完善的肺動脈高壓登記基礎設施。

關於多環芳烴商業策略的關鍵集團見解

在東協地區，肺動脈高壓（PAH）的商業機會與三級醫療機構容量的提升、超音波心臟超音波圖的普及以及專科藥物的逐步引入密切相關；然而，報銷機制的碎片化和右心導管檢查的普及程度不均仍然是限制因素。在海灣合作理事會（GCC）國家，由於對三級醫療的投資以及部分市場高成本PAH治療的普及，罕見疾病和心肺中心正在加強。歐盟擁有最完善的肺動脈高壓評估體系之一，其集中化的監管流程、國家衛生技術評估、成熟的藥物安全監測系統以及完善的臨床指南實施框架都為此提供了有力支持。

主要國家多環芳烴治療市場趨勢

美國是肺動脈高壓藥物市場成長的關鍵參與者，這得益於創新技術的快速普及、透過專科藥房的分銷、經認證的肺動脈高壓計畫以及對臨床試驗的大量投資。加拿大強調實證報銷和專家主導的治療，而墨西哥和巴西則面臨三級醫療、經濟負擔、診斷延遲和公共採購限制等方面的挑戰。在歐洲，英國、德國、法國、義大利和西班牙在肺動脈高壓領域擁有高水準的專業知識，積極參與註冊研究，並提供基於指南的治療，但其定價和准入決策受到國家醫療技術評估和報銷談判的影響。俄羅斯在臨床上仍然具有重要意義，但由於地緣政治因素、報銷和供應鏈問題，面臨商業性挑戰。

針對PAH領域製藥公司領導者的實用建議

製藥企業領導者應優先考慮產生反映現代肺動脈高壓 (PAH) 治療的基於風險的證據，這些證據應包括臨床進展、右心室功能、生活品質 (QOL)、住院率、運動耐量、NT-proBNP 反應以及真實臨床環境中的治療依從率等終點指標。與競爭對手的差異化不在於將產品孤立地進行定位，而在於證明其在聯合治療方案中的價值。

多環芳烴市場分析的調查方法

本執行摘要基於對公開且被廣泛引用的資料進行三角驗證，包括ESC/ERS肺動脈高壓指南、美國和歐洲監管資訊來源、WHO疾病分類、經同行評審的肺動脈高壓註冊研究、臨床試驗論文以及衛生技術檢驗（HTA）框架。市場分析著重於檢驗的臨床終點、已通過核准的治療類別、診斷標準以及已證實的區域可近性模式。

結論：PAH藥物市場的策略性展望

肺動脈高壓（PAH）市場正從以血管擴張劑主導的治療模式轉向一個更為複雜的時代轉變，這一轉變的特徵是緩解疾病、基於風險的聯合治療、真實世界數據以及人工智慧驅動的患者識別。這種轉變為能夠證明其永續臨床價值並成功應對複雜醫保體系的製藥公司帶來了巨大的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肺動脈高壓市場：依藥物類別分類

  • 內皮素受體拮抗劑
  • 磷酸二酯酶-5抑制劑
  • 類前列腺素

第8章 肺動脈高壓市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第9章 肺動脈高壓市場：依治療類型分類

  • 內皮素受體拮抗劑（ERA）
    • 波生坦
    • 安布里森坦
    • Macitentan
  • 磷酸二酯酶 5 (PDE-5) 抑制劑
    • Sildenafil
    • 他達拉非
  • 前列腺環素類似物
    • 前列醇
    • 曲前列尼爾
    • Iloprost
  • 可溶性鳥苷酸環化酶（sGC）促效劑

第10章 肺動脈高壓市場：依病患類型分類

  • 兒童
  • 成人
  • 老年人

第11章 肺動脈高壓市場：依最終用戶分類

  • 學術和研究機構
  • 診所
  • 醫院

第12章 肺動脈高壓市場：依通路分類

  • 離線
  • 線上

第13章 肺動脈高壓市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 肺動脈高壓市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 肺動脈高壓市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • CMP Pharma, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Gossamer Bio, Inc.
  • Gyre Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • United Therapeutics Corporation
Product Code: MRR-030D347B0AD6

The Pulmonary Arterial Hypertension Market is projected to grow by USD 16.45 billion at a CAGR of 7.73% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.77 billion
Estimated Year [2026] USD 10.46 billion
Forecast Year [2032] USD 16.45 billion
CAGR (%) 7.73%

Pulmonary arterial hypertension (PAH) is a rare, progressive form of pulmonary hypertension defined by remodeling of the small pulmonary arteries, elevated pulmonary vascular resistance, and eventual right-heart failure. It is classified as World Health Organization Group 1 pulmonary hypertension and includes idiopathic, heritable, drug- and toxin-associated, and connective tissue disease-associated PAH. Epidemiology studies and major registries consistently show low prevalence relative to chronic cardiopulmonary diseases, but high clinical burden, frequent hospitalization, and substantial treatment cost.

The PAH therapeutics landscape is anchored in three established pathways: endothelin receptor antagonism, nitric oxide-cGMP signaling, and prostacyclin signaling. The market is now entering a new phase with disease-modifying approaches, earlier risk-based treatment escalation, and deeper use of real-world evidence. For pharmaceutical leaders, growth is increasingly tied to differentiated clinical outcomes, combination therapy positioning, lifecycle management, and market access strategies that demonstrate measurable impact on functional class, six-minute walk distance, NT-proBNP, hospitalization, and survival-oriented risk scores.

Transformative Shifts in the PAH Treatment Landscape

The most important shift in PAH is the transition from symptom control toward earlier, risk-guided intervention. The 2022 ESC/ERS pulmonary hypertension guidelines reinforced comprehensive diagnostic workup, referral to expert centers, and multiparameter risk assessment, while also supporting upfront or early combination therapy for many patients. This has raised the commercial importance of therapies that integrate into sequential and combination regimens without compromising safety, tolerability, or adherence.

A second structural shift is the expansion beyond vasodilation. The 2024 U.S. regulatory approval of an activin signaling inhibitor introduced a treatment approach targeting vascular remodeling biology, reflecting a broader industry move toward disease-modifying mechanisms in pulmonary arterial hypertension. This is changing competitive benchmarks from short-term exercise capacity alone to durable risk reduction, time to clinical worsening, and right-ventricular function. Patent expirations and generic competition in legacy drug classes are also pressuring pricing, increasing the need for innovative therapies to prove incremental value through robust clinical and real-world outcomes.

Cumulative Impact of Artificial Intelligence on PAH Pharma

Artificial intelligence is having a cumulative impact across PAH discovery, diagnosis, trial design, and commercialization. In drug development, machine learning is being used to analyze omics datasets, identify molecular subtypes, repurpose compounds, and enrich trials for patients at higher risk of progression. These approaches are particularly relevant in PAH because patient populations are small, heterogeneous, and often diagnosed late.

In clinical and commercial execution, AI can support earlier detection by screening echocardiography reports, right-heart catheterization data, EHR notes, claims patterns, and biomarker trends for signals consistent with pulmonary hypertension. For pharmaceutical companies, this improves referral pathway mapping, patient finding, pharmacovigilance, and evidence generation. The strongest applications will be those governed by transparent validation, privacy safeguards, bias testing, and alignment with clinical guidelines, because PAH treatment decisions require confirmatory hemodynamic diagnosis and expert interpretation.

Key Regional Insights Across Global PAH Markets

North America remains the most commercially advanced PAH region, led by the United States, where specialty pharmacies, pulmonary hypertension centers, high adoption of advanced therapies, and payer-managed access shape treatment utilization. Canada benefits from specialist networks, public reimbursement pathways, and established clinical practice standards, though access timing can vary by province. Europe is similarly mature, with Germany, France, Italy, Spain, and the United Kingdom influenced by health technology assessment, guideline adherence, national reimbursement decisions, and strong pulmonary hypertension registry infrastructure.

Asia-Pacific is expanding as Japan, China, South Korea, Australia, and India improve specialist capacity, diagnostic imaging access, and rare disease policy frameworks. Japan and Australia show strong alignment with advanced therapy use and structured reimbursement, while China and India offer large potential patient pools but continue to face uneven diagnosis, referral delays, and reimbursement variability. Latin America, led by Brazil and Mexico, is developing through tertiary centers, public-private access models, and growing awareness of rare cardiopulmonary diseases. The Middle East, especially GCC markets, is investing in specialty care and advanced hospital infrastructure, while Africa remains constrained by limited right-heart catheterization access, late diagnosis, affordability gaps, and shortages of specialized pulmonary hypertension centers.

Key Group Insights for PAH Commercial Strategy

Within ASEAN, PAH opportunity is tied to rising tertiary hospital capacity, broader echocardiography access, and gradual adoption of specialty medicines, although reimbursement fragmentation and uneven availability of right-heart catheterization remain barriers. GCC countries are strengthening rare disease and cardiopulmonary centers, supported by investment in tertiary care and access to high-cost PAH therapies in selected markets. The European Union provides one of the most structured environments for pulmonary arterial hypertension assessment, with centralized regulatory pathways, national health technology assessments, established pharmacovigilance systems, and well-developed clinical guideline implementation.

BRICS markets combine high long-term demand potential with variable access. China and India are expanding diagnosis, specialty medicine availability, and local clinical research, Brazil has important public-sector access dynamics, and Russia faces supply and reimbursement complexity. G7 markets represent the highest-value segment for innovative PAH therapeutics because of specialist density, payer sophistication, advanced diagnostics, and early adoption of novel treatment options. NATO countries overlap substantially with high-income North American and European markets, where supply resilience, regulatory quality, cross-border research networks, and coordinated clinical standards support stable PAH commercialization.

Key Country Insights in the PAH Therapeutics Market

The United States is the anchor country for PAH pharmaceutical growth because of rapid uptake of innovation, specialty pharmacy distribution, accredited pulmonary hypertension programs, and high investment in clinical trials. Canada emphasizes evidence-based reimbursement and specialist-led care, while Mexico and Brazil show opportunity through tertiary centers but face affordability, diagnostic delay, and public procurement constraints. In Europe, the United Kingdom, Germany, France, Italy, and Spain have strong pulmonary hypertension expertise, registry participation, and guideline-based care, though pricing and access decisions are shaped by national health technology assessment and reimbursement negotiations. Russia remains clinically relevant but commercially complex due to geopolitical, reimbursement, and supply chain considerations.

China is scaling specialty medicine access, rare disease awareness, and hospital-based diagnosis, making it a critical long-term market for pulmonary arterial hypertension therapies. India's PAH burden remains underdiagnosed, but urban cardiac and pulmonary centers are improving detection and referral pathways. Japan has high-quality specialty care, established clinical guideline alignment, and advanced adoption of PAH therapies, while Australia benefits from structured reimbursement, specialist referral pathways, and strong rare disease policy infrastructure. South Korea combines advanced diagnostics, strong hospital infrastructure, and high specialty care capacity, creating favorable conditions for uptake of innovative PAH treatment options.

Actionable Recommendations for PAH Pharmaceutical Leaders

Pharmaceutical leaders should prioritize risk-based evidence generation that reflects modern PAH care, including clinical worsening endpoints, right-ventricular function, quality of life, hospitalization, exercise capacity, NT-proBNP response, and real-world persistence. Differentiation will depend on demonstrating value within combination therapy pathways rather than positioning products in isolation.

Companies should build integrated patient-finding strategies with expert centers, payers, and compliant data partners to reduce diagnostic delay. Market access teams need country-specific evidence dossiers that address rare disease value, comparative effectiveness, treatment sequencing, and long-term outcomes. Lifecycle strategies should include formulation improvements, adherence support, companion diagnostics where scientifically justified, and post-marketing studies that validate outcomes in idiopathic, heritable, connective tissue disease-associated, congenital heart disease-associated, and other PAH subgroups.

Research Methodology for PAH Market Analysis

This executive summary is based on triangulation of publicly available and widely cited sources, including ESC/ERS pulmonary hypertension guidelines, U.S. and European regulatory information, WHO disease classification, peer-reviewed PAH registries, clinical trial publications, and health technology assessment frameworks. Market interpretation emphasizes verified clinical endpoints, approved therapeutic classes, diagnostic standards, and documented regional access patterns.

The research approach combines secondary evidence review, competitive landscape mapping, regional healthcare infrastructure assessment, and synthesis of payer and policy signals. No unsupported market-size, market-share, or growth-rate claims are used; conclusions are grounded in observable treatment trends, regulatory milestones, epidemiology literature, reimbursement mechanisms, and established clinical practice patterns.

Conclusion: Strategic Outlook for PAH Pharma

The PAH market is moving from a vasodilator-led treatment model to a more sophisticated era defined by disease modification, risk-based combination therapy, real-world evidence, and AI-enabled patient identification. This evolution creates significant opportunity for pharmaceutical companies that can demonstrate durable clinical value and navigate complex reimbursement systems.

Success will depend on aligning innovation with guideline-based care, specialist center workflows, and region-specific access realities. Companies that combine strong clinical evidence with patient-centered support, transparent AI use, ethical data governance, and resilient global supply strategies will be best positioned in the next phase of pulmonary arterial hypertension care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pulmonary Arterial Hypertension Market, by Drug Class

  • 7.1. Endothelin Receptor Antagonists
  • 7.2. Phosphodiesterase-5 Inhibitors
  • 7.3. Prostanoids

8. Pulmonary Arterial Hypertension Market, by Route Of Administration

  • 8.1. Intravenous
  • 8.2. Oral
  • 8.3. Subcutaneous

9. Pulmonary Arterial Hypertension Market, by Treatment Type

  • 9.1. Endothelin Receptor Antagonists (ERAs)
    • 9.1.1. Bosentan
    • 9.1.2. Ambrisentan
    • 9.1.3. Macitentan
  • 9.2. Phosphodiesterase-5 (PDE-5) Inhibitors
    • 9.2.1. Sildenafil
    • 9.2.2. Tadalafil
  • 9.3. Prostacyclin Analogues
    • 9.3.1. Epoprostenol
    • 9.3.2. Treprostinil
    • 9.3.3. Iloprost
  • 9.4. Soluble Guanylate Cyclase (sGC) Stimulators

10. Pulmonary Arterial Hypertension Market, by Patient Type

  • 10.1. Pediatric
  • 10.2. Adult
  • 10.3. Geriatric

11. Pulmonary Arterial Hypertension Market, by End User

  • 11.1. Academic & Research Institutions
  • 11.2. Clinics
  • 11.3. Hospitals

12. Pulmonary Arterial Hypertension Market, by Distribution

  • 12.1. Offline
  • 12.2. Online

13. Pulmonary Arterial Hypertension Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Pulmonary Arterial Hypertension Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pulmonary Arterial Hypertension Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Alembic Pharmaceuticals Limited
  • 17.2. AstraZeneca PLC
  • 17.3. Aurobindo Pharma Limited
  • 17.4. Bayer AG
  • 17.5. Boehringer Ingelheim GmbH
  • 17.6. Cipla Limited
  • 17.7. CMP Pharma, Inc.
  • 17.8. Dr. Reddy's Laboratories Limited
  • 17.9. Eli Lilly and Company
  • 17.10. Gilead Sciences, Inc.
  • 17.11. GlaxoSmithKline PLC
  • 17.12. Gossamer Bio, Inc.
  • 17.13. Gyre Therapeutics, Inc.
  • 17.14. Hikma Pharmaceuticals PLC
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Lupin Limited
  • 17.17. Merck KGaA
  • 17.18. Novartis AG
  • 17.19. Pfizer, Inc.
  • 17.20. Sun Pharmaceutical Industries Limited
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Torrent Pharmaceuticals Limited
  • 17.23. United Therapeutics Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHOSPHODIESTERASE-5 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHOSPHODIESTERASE-5 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHOSPHODIESTERASE-5 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTANOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROSTANOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTANOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BOSENTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOSENTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BOSENTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMBRISENTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AMBRISENTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMBRISENTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MACITENTAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MACITENTAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MACITENTAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SILDENAFIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SILDENAFIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SILDENAFIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TADALAFIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TADALAFIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TADALAFIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTACYCLIN ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTACYCLIN ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTACYCLIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EPOPROSTENOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EPOPROSTENOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EPOPROSTENOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TREPROSTINIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TREPROSTINIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TREPROSTINIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ILOPROST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ILOPROST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ILOPROST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 163. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 183. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 193. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 195. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 203. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 224. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 294. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS), 2018-2032 (USD MILLION)
  • TABLE 314. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE